Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein

Biochemical Pharmacology

Volumn 70, Issue 4, 2005, Pages 627-639

  Zhang, Shuzhong ^a   Yang, Xinning ^a   Coburn, Robert A ^a   Morris, Marilyn E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Breast cancer resistance protein; Flavonoids; Membrane transport; Mitoxantrone transport; Quantitative structure activity relationships; Structure activity relationships

Indexed keywords

2' HYDROXY ALPHA NAPHTHOFLAVONE; 5,6,7 TRIMETHOXYFLAVONE; 5,7 DIMETHOXYFLAVONE; 6,2',3' TRIMETHOXYFLAVONE; 6,4' DIMETHOXY 3 HYDROXYFLAVONE; 7 HYDROXYFLAVANONE; 7 METHOXYFLAVANONE; 7,8 DIHYDROXYFLAVONE; 8 METHYLFLAVONE; ABC TRANSPORTER; ALPHA NAPHTHOFLAVONE; APIGENIN; BAICALEIN; BREAST CANCER RESISTANCE PROTEIN; CHALCONE; CHRYSIN; DAIDZEIN; FLAVANONE; FLAVONE; FLAVONOID; GALANGIN; GENISTEIN; GLYCOPROTEIN P; HESPERETIN; ISOKAEMPFERIDE; MITOXANTRONE; NARINGENIN; PROTEIN INHIBITOR; SILIBININ; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BIOACCUMULATION; CELLULAR DISTRIBUTION; CHEMICAL BOND; CONTROLLED STUDY; DRUG EFFECT; DRUG HYDROXYLATION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ALGORITHMS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; FLAVONOIDS; HUMANS; NEOPLASM PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 22144481699     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.05.017     Document Type: Article

References (41)

1. S. Zhang, X. Yang, and M.E. Morris Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport Pharm Res 21 7 2004 1263 1273
2. J.B. Harborne, and C.A. Williams Advances in flavonoid research since Phytochemistry 55 6 2000 481 504
3. M.G. Hertog, E.J. Feskens, P.C. Hollman, M.B. Katan, and D. Kromhout Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study Lancet 342 8878 1993 1007 1011
4. B.H. Havsteen The biochemistry and medical significance of the flavonoids Pharmacol Ther 96 2-3 2002 67 202
5. H.P. Lee, L. Gourley, S.W. Duffy, J. Esteve, J. Lee, and N.E. Day Dietary effects on breast-cancer risk in Singapore Lancet 337 8751 1991 1197 1200
6. S.M. Potter, J.A. Baum, H. Teng, R.J. Stillman, N.F. Shay, and J.W. Erdman Jr. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women Am J Clin Nutr 68 6 Suppl 1998 1375S 1379S
7. E. Middleton Jr., C. Kandaswami, and T.C. Theoharides The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer Pharmacol Rev 52 4 2000 673 751
8. G.K. Dresser, D.G. Bailey, B.F. Leake, U.I. Schwarz, P.A. Dawson, and D.J. Freeman Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine Clin Pharmacol Ther 71 1 2002 11 20
9. S.L. Hsiu, Y.C. Hou, Y.H. Wang, C.W. Tsao, S.F. Su, and P.D. Chao Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats Life Sci 72 3 2002 227 235
10. F. Ruschitzka, P.J. Meier, M. Turina, T.F. Luscher, and G. Noll Acute heart transplant rejection due to Saint John's wort Lancet 355 9203 2000 548 549
11. S. Zhang, X. Yang, and M.E. Morris Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport Mol Pharmacol 65 5 2004 1208 1216
12. H.C. Cooray, T. Janvilisri, H.W. van Veen, S.B. Hladky, and M.A. Barrand Interaction of the breast cancer resistance protein with plant polyphenols Biochem Biophys Res Commun 317 1 2004 269 275
13. R. Allikmets, L.M. Schriml, A. Hutchinson, V. Romano-Spica, and M. Dean A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance Cancer Res 58 23 1998 5337 5339
14. L.A. Doyle, W. Yang, L.V. Abruzzo, T. Krogmann, Y. Gao, and A.K. Rishi A multidrug resistance transporter from human MCF-7 breast cancer cells Proc Natl Acad Sci USA 95 26 1998 15665 15670
15. K. Miyake, L. Mickley, T. Litman, Z. Zhan, R. Robey, and B. Cristensen Molecular cloning of cDNAs, which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes Cancer Res 59 1 1999 8 13
16. T. Litman, T.E. Druley, W.D. Stein, and S.E. Bates From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance Cell Mol Life Sci 58 7 2001 931 959
17. L.A. Doyle, and D.D. Ross Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) Oncogene 22 47 2003 7340 7358
18. D.D. Ross, J.E. Karp, T.T. Chen, and L.A. Doyle Expression of breast cancer resistance protein in blast cells from patients with acute leukemia Blood 96 1 2000 365 368
19. A. Kanzaki, M. Toi, K. Nakayama, H. Bando, M. Mutoh, and T. Uchida Expression of multidrug resistance-related transporters in human breast carcinoma Jpn J Cancer Res 92 4 2001 452 458
20. J.M. Sargent, C.J. Williamson, M. Maliepaard, A.W. Elgie, R.J. Scheper, and C.G. Taylor Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia Br J Haematol 115 2 2001 257 262
21. D.M. van der Kolk, E. Vellenga, G.L. Scheffer, M. Muller, S.E. Bates, and R.J. Scheper Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia Blood 99 10 2002 3763 3770
22. D. Steinbach, W. Sell, A. Voigt, J. Hermann, F. Zintl, and A. Sauerbrey BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia Leukemia 16 8 2002 1443 1447
23. R.E. Friedrich, C. Punke, and A. Reymann Expression of multi-drug resistance genes (mdr1, mrp1, bcrp) in primary oral squamous cell carcinoma In Vivo 18 2 2004 133 147
24. M. Maliepaard, G.L. Scheffer, I.F. Faneyte, M.A. van Gastelen, A.C. Pijnenborg, and A.H. Schinkel Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues Cancer Res 61 8 2001 3458 3464
25. H.C. Cooray, C.G. Blackmore, L. Maskell, and M.A. Barrand Localisation of breast cancer resistance protein in microvessel endothelium of human brain Neuroreport 13 16 2002 2059 2063
26. S. Cisternino, C. Mercier, F. Bourasset, F. Roux, and J.M. Scherrmann Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier Cancer Res 64 9 2004 3296 3301
27. J.W. Jonker, J.W. Smit, R.F. Brinkhuis, M. Maliepaard, J.H. Beijnen, and J.H. Schellens Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan J Natl Cancer Inst 92 20 2000 1651 1656
28. C.M. Kruijtzer, J.H. Beijnen, H. Rosing, W.W. ten Bokkel Huinink, M. Schot, and R.C. Jewell Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918 J Clin Oncol 20 13 2002 2943 2950
29. Y. Imai, S. Tsukahara, S. Asada, and Y. Sugimoto Phytoestrogens/ flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance Cancer Res 64 12 2004 4346 4352
30. R.W. Robey, K. Steadman, O. Polgar, K. Morisaki, M. Blayney, and P. Mistry Pheophorbide a is a specific probe for ABCG2 function and inhibition Cancer Res 64 4 2004 1242 1246
31. S.K. Rabindran, H. He, M. Singh, E. Brown, K.I. Collins, and T. Annable Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C Cancer Res 58 24 1998 5850 5858
32. R.W. Robey, Y. Honjo, A. van de Laar, K. Miyake, J.T. Regis, and T. Litman A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2) Biochim Biophys Acta 1512 2 2001 171 182
33. E. Nikander, A. Kilkkinen, M. Metsa-Heikkila, H. Adlercreutz, P. Pietinen, and A. Tiitinen A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients Obstet Gynecol 101 6 2003 1213 1220
34. M. Aklilu, H.L. Kindler, R.C. Donehower, S. Mani, and E.E. Vokes Phase II study of flavopiridol in patients with advanced colorectal cancer Ann Oncol 14 8 2003 1270 1273
35. A. Boumendjel, A. Di Pietro, C. Dumontet, and D. Barron Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance Med Res Rev 22 5 2002 512 529
36. J.J. van Zanden, L. Geraets, H.M. Wortelboer, P.J. van Bladeren, I.M. Rietjens, and N.H. Cnubben Structural requirements for the flavonoid-mediated modulation of glutathione S-transferase P1-1 and GS-X pump activity in MCF7 breast cancer cells Biochem Pharmacol 67 8 2004 1607 1617
37. A. Boumendjel, F. Bois, C. Beney, A.M. Mariotte, G. Conseil, and A. Di Pietro B-ring substituted 5,7-dihydroxyflavonols with high-affinity binding to P-glycoprotein responsible for cell multidrug resistance Bioorg Med Chem Lett 11 1 2001 75 77
38. G. Conseil, H. Baubichon-Cortay, G. Dayan, J.M. Jault, D. Barron, and A. Di Pietro Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein Proc Natl Acad Sci USA 95 17 1998 9831 9836
39. B. Hoffman, S.J. Cho, W. Zheng, S. Wyrick, D.E. Nichols, and R.B. Mailman Quantitative structure-activity relationship modeling of dopamine D(1) antagonists using comparative molecular field analysis, genetic algorithms-partial least-squares, and K nearest neighbor methods J Med Chem 42 17 1999 3217 3226
40. S. Wanchana, F. Yamashita, and M. Hashida QSAR analysis of the inhibition of recombinant CYP 3A4 activity by structurally diverse compounds using a genetic algorithm-combined partial least squares method Pharm Res 20 9 2003 1401 1408
41. A. Golbraikh, and A. Tropsha Beware of q2! J Mol Graph Model 20 4 2002 269 276